ACCESS-1 STUDY

A clinical study for adults with paroxysmal nocturnal hemoglobinuria (PNH) who are new to or have not recently received complement inhibitor treatment.

As someone living with PNH, you may be interested in learning about a clinical research study sponsored by Regeneron Pharmaceuticals. The **ACCESS-1 Study** is comparing the effects of the experimental study drug combination **pozelimab** and **cemdisiran** to an already approved treatment called ravulizumab in adults with PNH.

Who is the study for?

This study is for adults 18 years of age or older who:

- Have a confirmed diagnosis of PNH.
- Have active disease (≥1 sign or symptom of PNH) or history of blood transfusion due to PNH within the last 3 months.
- Have not been treated with eculizumab within the last 3 months or ravulizumab within the last 6 months.
- NOTE: Other study criteria apply.

What happens during the study?

You will first have tests and health checks to see if you qualify for the study (Screening Period). If eligible, you will enter a 26-week Treatment Period to receive study treatment and have doctor visits to check on your health. Home healthcare or virtual visits may be available for certain visits. You will have continuous care throughout the study and will be closely monitored for any changes in your health.

What study treatment will I receive?

You will be randomly assigned to receive either the experimental study drug combination (pozelimab + cemdisiran) or ravulizumab.

Pozelimab + cemdisiran
are injected under the skin.*

**The first dose of pozelimab is given as an infusion.*

Ravulizumab
is given as an infusion, which means slowly through a needle into a vein in the arm.

Participation is voluntary, and if you decide to join, you can choose to stop participating at any time. You may or may not directly benefit from participating in the study, but information learned could help others with PNH in the future.

If you would like to learn more about the ACCESS-1 Study, contact:

_____ **at** _____

REGENERON